Cargando…

CeO(2)@NH(2) functionalized electrodes for the rapid detection of SARS-CoV-2 spike receptor binding domain

A detection method based on an electrochemical aptasensor has been developed as an alternative fast, portable, simple, inexpensive, and high-accuracy detection method for detecting the SARS-CoV-2 Spike Receptor Binding Domain (spike RBD). The CeO(2)@NH(2) functionalized Screen Printed Carbon Electro...

Descripción completa

Detalles Bibliográficos
Autores principales: Triastuti, Ayu, Zakiyyah, Salma Nur, Gaffar, Shabarni, Anshori, Isa, Surawijaya, Akhmadi, Hidayat, Darmawan, Wiraswati, Hesti Lina, Yusuf, Muhammad, Hartati, Yeni Wahyuni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933633/
https://www.ncbi.nlm.nih.gov/pubmed/36816083
http://dx.doi.org/10.1039/d2ra07560a
Descripción
Sumario:A detection method based on an electrochemical aptasensor has been developed as an alternative fast, portable, simple, inexpensive, and high-accuracy detection method for detecting the SARS-CoV-2 Spike Receptor Binding Domain (spike RBD). The CeO(2)@NH(2) functionalized Screen Printed Carbon Electrode (SPCE) was used to immobilize an aminated aptamer of spike RBD protein via glutaraldehyde as a linker. The aptamer's interaction with the SARS-CoV-2 Spike RBD was measured via the [Fe(CN)(6)](4−/3−) redox system signal. Experimental conditions were optimized using a Box–Behnken experimental design and showed that the optimal conditions of the SARS-CoV-2 aptasensor were 1.5 ng mL(−1) of aptamer, immobilization of aptamer for 60 minutes, and Spike RBD incubation for 10 minutes. The developed aptasensor was able to detect the standard SARS-CoV-2 Spike RBD with a detection limit of 0.017 ng mL(−1) in the range of 0.001–100 ng mL(−1). This aptasensor was used to detect salivary and oropharyngeal swab samples of normal individuals with the addition of Spike RBD, and the recoveries were 92.96% and 96.52%, respectively. The testing on nasopharyngeal swab samples of COVID-19 patients showed that the aptasensor results were comparable with the qRT-PCR results. Thus, the developed aptasensor has the potential to be applied as a SARS-CoV-2 rapid test method for clinical samples.